Ken Griffin Hepion Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	BUY	$0.31 - $1.06 $1,333 - $4,558	4,300 Added 14.1%	34,800 $27,000
Q4 2022 Feb 14, 2023	SELL	$0.27 - $11.9 $4,644 - $204,680	-17,200 Reduced 36.06%	30,500 $9,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $10.4 $1,173 - $23,920	2,300 Added 5.07%	47,700 $24,000

Ticker HEPA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,229,600
Market Cap $49.5M
Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.